Tyra Biosciences, Inc.
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
TYRA$21.15+1.2%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share and per share data)
| September 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| (unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $61,951 | $91,966 |
| Marketable securities | 212,973 | 249,475 |
| Prepaid expenses and other current assets | 6,292 | 6,022 |
| Total current assets | 281,216 | 347,463 |
| Restricted cash | 1,000 | 1,000 |
| Property and equipment, net | 1,346 | 1,651 |
| Right-of-use assets | 5,699 | 6,068 |
| Other long-term assets | 12,590 | 7,376 |
| Total assets | $301,851 | $363,558 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $1,991 | $590 |
| Lease liabilities, current | 456 | 412 |
| Accrued expenses and other current liabilities | 13,432 | 13,592 |
| Total current liabilities | 15,879 | 14,594 |
| Lease liabilities, noncurrent | 5,463 | 5,810 |
| Other long-term liabilities | — | 3 |
| Total liabilities | 21,342 | 20,407 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 50,000,000 shares authorized at September 30, 2025 and December 31, 2024; no shares issued and outstanding at September 30, 2025 and December 31, 2024. | — | — |
| Common stock, $0.0001 par value; 500,000,000 shares authorized at September 30, 2025 and December 31, 2024; 53,318,198 and 50,754,262 shares issued at September 30, 2025 and December 31, 2024, respectively, and 53,318,198 and 50,749,945 shares outstanding at September 30, 2025 and December 31, 2024, respectively. | 5 | 5 |
| Additional paid-in capital | 617,486 | 593,687 |
| Accumulated other comprehensive income | 442 | 770 |
| Accumulated deficit | (337,424) | (251,311) |
| Total stockholders’ equity | 280,509 | 343,151 |
| Total liabilities and stockholders’ equity | $301,851 | $363,558 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.